Protalix BioTherapeutics, Inc. (PLX)Healthcare | Biotechnology | Hackensack, United States | NYSE American
2.75 USD
-0.03
(-1.079%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 2.80 +0.05 (1.818%) ⇧ (Oct. 13, 2026, 7:50 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:56 a.m. EDT
The investment case here is a stark dichotomy between explosive recent earnings and a precarious historical trajectory. Fundamentally, the company is firing on all cylinders with 27% revenue growth and a massive 234% jump in Q1 2026, alongside healthy margins and a fortress-like balance sheet with negligible debt. These metrics suggest a high-quality turnaround story. However, the long-term rating remains neutral because the stock has been a volatile rollercoaster over the last decade, swinging wildly between 1.00 and 6.00 without establishing a stable floor. The market hasn't yet rewarded this recent success with a sustained price trend, keeping the long-term outlook cautious despite the bright fundamentals. For the short term, the momentum is clearly shifting upward, supported by a moderate statistical forecast and aggressive call buying at distant strikes, suggesting traders are pricing in a continuation of this recovery. Yet, the lack of a dividend and the history of erratic performance mean this is still a high-risk play on a turnaround, not a safe haven. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.036427 |
| AutoARIMA | 0.070346 |
| AutoETS | 0.071342 |
| MSTL | 0.074726 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 0.79 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.354 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.894 |
| Revenue per Share | 1.012 |
| Market Cap | 221,572,016 |
| Trailing P/E | 11.96 |
| Forward P/E | 4.44 |
| Beta | -0.09 |
| Profit Margins | 23.50% |
| Website | https://www.protalix.com |
As of Oct. 10, 2026, 5:56 a.m. EDT: Speculators are positioning for a modest upside move with heavy call volume concentrated at the $5.00 strike, which represents a significant gap from current prices. This suggests a speculative bet on a binary event or rapid recovery rather than steady accumulation. Conversely, put activity is almost entirely out-of-the-money, indicating limited hedging against immediate downside, though the implied volatility on near-term puts is elevated relative to calls, hinting at some fear of a sharp drop if the $5.00 target fails.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.11646581 |
| Address1 | 2 University Plaza |
| Address2 | Suite 100 |
| All Time High | 912.5 |
| All Time Low | 0.7 |
| Ask | 0.0 |
| Ask Size | 3,800 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 987,320 |
| Average Daily Volume3 Month | 749,955 |
| Average Volume | 749,955 |
| Average Volume10Days | 987,320 |
| Beta | -0.088 |
| Bid | 0.0 |
| Bid Size | 5,400 |
| Board Risk | 7 |
| Book Value | 0.886 |
| City | Hackensack |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.75 |
| Current Ratio | 2.938 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.785 |
| Day Low | 2.735 |
| Debt To Equity | 12.894 |
| Display Name | Protalix BioTherapeutics |
| Dividend Date | 1,576,800,000 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,536,000 |
| Earnings Call Timestamp Start | 1,786,536,000 |
| Earnings Growth | 22.411 |
| Earnings Quarterly Growth | 22.03 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | 24,860,000 |
| Ebitda Margins | 0.30836 |
| Enterprise To Ebitda | 7.648 |
| Enterprise To Revenue | 2.358 |
| Enterprise Value | 190,123,008 |
| Eps Forward | 0.62 |
| Eps Trailing Twelve Months | 0.23 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.587 |
| Fifty Day Average Change | 0.1630001 |
| Fifty Day Average Change Percent | 0.06300739 |
| Fifty Two Week Change Percent | 11.646581 |
| Fifty Two Week High | 3.19 |
| Fifty Two Week High Change | -0.44000006 |
| Fifty Two Week High Change Percent | -0.13793105 |
| Fifty Two Week Low | 1.6 |
| Fifty Two Week Low Change | 1.15 |
| Fifty Two Week Low Change Percent | 0.71875 |
| Fifty Two Week Range | 1.6 - 3.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 895,239,000,000 |
| Float Shares | 77,447,074 |
| Forward Eps | 0.62 |
| Forward P E | 4.435484 |
| Free Cashflow | 2,992,375 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 226 |
| Fullday Change | 0.059999943 |
| Fullday Change Percent | 2.1582713 |
| Fullday Price | 2.75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.45768002 |
| Gross Profits | 36,898,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03878 |
| Held Percent Institutions | 0.18417 |
| Implied Shares Outstanding | 80,571,642 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,576,800,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey. |
| Long Name | Protalix BioTherapeutics, Inc. |
| Market | us_market |
| Market Cap | 221,572,016 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_941520 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 18,945,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 225,600,597 |
| Number Of Analyst Opinions | 2 |
| Open | 2.8 |
| Operating Cashflow | 9,923,000 |
| Operating Margins | 0.23482001 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 201 696 9345 |
| Post Market Change | 0.049999952 |
| Post Market Change Percent | 1.8181801 |
| Post Market Price | 2.8 |
| Post Market Time | 1,791,935,445 |
| Previous Close | 2.78 |
| Price Hint | 4 |
| Price To Book | 3.1038375 |
| Price To Sales Trailing12 Months | 2.7483845 |
| Profit Margins | 0.23499 |
| Quick Ratio | 1.821 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -1.07914 |
| Regular Market Day High | 2.785 |
| Regular Market Day Low | 2.735 |
| Regular Market Day Range | 2.735 - 2.785 |
| Regular Market Open | 2.8 |
| Regular Market Previous Close | 2.78 |
| Regular Market Price | 2.75 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 966,787 |
| Return On Assets | 0.15419 |
| Return On Equity | 0.31235 |
| Revenue Growth | 0.271 |
| Revenue Per Share | 1.012 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 80,571,642 |
| Shares Percent Shares Out | 0.0377 |
| Shares Short | 3,040,042 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,165,145 |
| Short Name | Protalix BioTherapeutics, Inc. |
| Short Percent Of Float | 0.039300002 |
| Short Ratio | 4.16 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PLX |
| Target High Price | 12.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 40,656,000 |
| Total Cash Per Share | 0.505 |
| Total Debt | 9,207,000 |
| Total Revenue | 80,619,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.23 |
| Trailing P E | 11.956522 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.3632 |
| Two Hundred Day Average Change | 0.38680005 |
| Two Hundred Day Average Change Percent | 0.1636764 |
| Type Disp | Equity |
| Volume | 966,787 |
| Website | https://www.protalix.com |
| Zip | 7,601 |